NCT06001073 Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics
| NCT ID | NCT06001073 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Affiliated Hospital Xi'an Jiaotong University |
| Condition | Coronary Artery Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 25,000 participants |
| Start Date | 2022-12-05 |
| Primary Completion | 2028-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 25,000 participants in total. It began in 2022-12-05 with a primary completion date of 2028-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The etiology and specific pathogenesis of many cardiovascular diseases such as coronary atherosclerosis, cardiomyopathy, atrial fibrillation, and stroke are still unclear. Improving diagnosis and treatment, clarifying the pathogenesis, and providing scientific basis for the prevention and treatment are hot research topics in the study of cardiovascular and cerebrovascular diseases. This study intends to collect clinical data and biological specimen data of patients with cardiovascular and cerebrovascular diseases who meet the inclusion and exclusion criteria, and use multi-omics technology to deeply understand the pathogenic mechanisms of cardiovascular and cerebrovascular diseases and provide new ideas for specific and individualized treatment of patients with cardiovascular and cerebrovascular diseases, to construct early predictive prognostic models and provide a basis for effective treatment of clinical practice in patients with cardiovascular and cerebrovascular diseases.
Eligibility Criteria
Inclusion Criteria: * Patients who are regularly visited and followed up in the appropriate patient; department. * All patients met at least one of the following diagnostic criteria for cardiovascular and cerebrovascular diseases: * coronary artery disease group; * arrhythmia group; * heart valve disease group; * aortic dissection group; * cardiac masses group; * myocarditis group; * hypertension group; * cardiomyopathy group; * structural heart disease group; * ischemic cerebrovascular disease group; * hemorrhagic cerebrovascular disease group; * intracranial space occupying lesion group. Exclusion Criteria: * Age \<3 years or \>80 years old; * Pregnant and lactating women; * The patient declined to provide informed consent to participate in the study; * None of the above was met, but the patient was temporarily unable to sign the informed consent form due to coma and other reasons, and no legal representative signed it instead. Depending on the patient's condition, the patient may not be able to regain consciousness and sign the informed consent form.
Contact & Investigator
Gouliang Li
PRINCIPAL INVESTIGATOR
First Affiliated Hospital Xi'an Jiaotong University
Frequently Asked Questions
Who can join the NCT06001073 clinical trial?
This trial is open to participants of all sexes, aged 3 Years or older, up to 80 Years, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06001073 currently recruiting?
Yes, NCT06001073 is actively recruiting participants. Contact the research team at liguoliang_med@163.com for enrollment information.
Where is the NCT06001073 trial being conducted?
This trial is being conducted at Xi'an, China.
Who is sponsoring the NCT06001073 clinical trial?
NCT06001073 is sponsored by First Affiliated Hospital Xi'an Jiaotong University. The principal investigator is Gouliang Li at First Affiliated Hospital Xi'an Jiaotong University. The trial plans to enroll 25,000 participants.